A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

Expanding serotype coverage of pneumococcal conjugate vaccines (PCVs) to target prevailing disease-causing serotypes could further reduce disease burden. To address this need, 2 different PCVs have been investigated: a 20-valent PCV (PCV20; includes the 13 serotypes in the 13-valent PCV [PCV13] plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitz-Patrick, David, Young Jr, Mariano, Scott, Daniel A., Scully, Ingrid L., Baugher, Gary, Peng, Yahong, Jansen, Kathrin U., Gruber, William, Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189073/
https://www.ncbi.nlm.nih.gov/pubmed/33545022
http://dx.doi.org/10.1080/21645515.2020.1863177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189073/
https://www.ncbi.nlm.nih.gov/pubmed/33545022
http://dx.doi.org/10.1080/21645515.2020.1863177

Ejemplares similares